Paper Review Records
All Paper Review Records
30 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
EHA Guidelines for the use and reporting of patient‐reported outcomes in clinical trials of classical Philadelphia chromosome‐negative myeloproliferative neoplasms
Esther Natalie Oliva; Tatyana Ionova; Marta Sobas; Peter Loeffelhardt; Edward Laane; Sam SalekShow moreShow less
1. Hematology Department London North West University Healthcare NHS Trust London United Kingdom; 2. Quality of Life Monitoring Unit Saint Petersburg State University Hospital St. Petersburg Russia; 3. Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation Wroclaw Medical University Wrocław Poland; 4. Global MPN Scientific Foundation Barcelona Spain; 5. Hematology–Oncology Clinic, University of Tartu Tartu Estonia; 6. School of Health, Medicine and Life Sciences University of Hertfordshire Hatfield United KingdomShow moreShow less
Differential recovery of macrophage iron deficiency by oral iron formulations determines inflammation and autocrine hepcidin production in iron‐deficiency anemia
Ada Antypiuk; Michela Asperti; Richa Sharma; Shobana Navaneethabalakrishnan; Navdeep Jhita; Quentinn Pearce; James E. Cox; Elisa Brilli; Germano Tarantino; Francesca VinchiShow moreShow less
1. Iron Research Laboratory Lindlsey F. Kimball Research Institute, New York Blood Center New York New York United States; 2. Department of Theoretical and Applied Sciences eCampus University Novedrate Como Italy; 3. Department of Molecular and Translational Medicine University of Brescia Brescia Italy; 4. Department of Pediatric Hematology/Oncology Emory University School of Medicine Atlanta Georgia United States; 5. Aflac Cancer and Blood Disorders Center Children's Healthcare of Atlanta Atlanta Georgia United States; 6. Solve Sickle Cell Initiative Atlanta Georgia United States; 7. Department of Biochemistry University of Utah Salt Lake City Utah United States; 8. Metabolomics, Mass Spectrometry, and Proteomics Core University of Utah Salt Lake City Utah United States; 9. Department of R&D PharmaNutra S.p.A. Pisa ItalyShow moreShow less
Maladaptive DNA damage responses impair CD8 T‐cell fitness after allogeneic stem cell transplantation
Tobias Ronny Haage; Domenica Saul; Romy Böttcher‐Loschinski; Martin Böttcher; Simon Völkl; Andreas Mackensen; Matthias Leisegang; Maurice Michel; Denise Walther; Dimitrios MougiakakosShow moreShow less
1. Department for Hematology, Oncology, Cell‐ and Radiotherapy Otto von Guericke University Magdeburg Germany; 2. Department of Internal Medicine 5, Hematology and Oncology Friedrich Alexander Universität Erlangen‐Nürnberg and Universitätsklinikum Erlangen Erlangen Germany; 3. Department of Oncology and Pathology, Science for Life Laboratory and Center for Molecular Medicine Karolinska Institute and Karolinska Hospital Stockholm Sweden; 4. Magdeburg Center for Cell‐ and Immunotherapy Otto von Guericke University Magdeburg GermanyShow moreShow less
Low tumor burden follicular lymphoma: The state of the art
Greg Hapgood; Joshua Tobin; Robert Kridel; Brad KahlShow moreShow less
1. Department of Cancer Services Princess Alexandra Hospital Brisbane Queensland Australia; 2. School of Medicine University of Queensland Brisbane Queensland Australia; 3. Princess Margaret Cancer Centre, UHN Toronto Ontario Canada; 4. Division of Medicine Washington University School of Medicine St. Louis Missouri United StatesShow moreShow less
Infections and their determinants in patients with non‐Hodgkin lymphoma receiving bispecific T‐cell antibodies: Results from an international multicenter cohort study
Zainab Shahid; Michelle Okwali; Ashlee Joseph; David Nemirovsky; Derkach Andriy; Clare Grieve; Rafaella Tringale; Reid Merryman; Aaron Zou; Silvia Ferrari; Monica Rondi; Sean Harrop; Divya Somasekharannair; Jennifer Crombie; Gilles Salles; Giuseppe Gritti; Michael Dickinson; Lorenzo FalchiShow moreShow less
1. Infectious Disease Service Memorial Sloan Kettering Cancer Center New York New York United States; 2. Lymphoma Service Memorial Sloan Kettering Cancer Center New York New York United States; 3. Epidemiology & Biostatistics Memorial Sloan Kettering Cancer Center New York New York United States; 4. Dana Farber Cancer Institute Boston Massachusetts United States; 5. Papa Giovanni XXIII Hospital Bergamo Italy; 6. Peter MacCallum Cancer Centre Melbourne Victoria AustraliaShow moreShow less
“A long bristling road full of adventure, full of discovery” gene therapy approaches in transfusion‐dependent thalassemia: The EHA‐EBMT consensus paper
Lucia De Franceschi; Emanuele AngelucciShow moreShow less
1. University of Verona and Azienda Ospedaliera Integrata Verona Italy; 2. IRCCS Ospedale Policlinico San Martino Genova ItalyShow moreShow less
FAQ
How long does HemaSphere take to review a manuscript?
As of 2026-11-17, CrushSCI has 30 complete review records for HemaSphere. The fastest paper went from submission to acceptance in 5 days (Shooting the messenger: Ecosystem approaches in haematology, received 2026-07-01, accepted 2026-07-06); the slowest took 251 days. The average is 107.5 days and the median is 91 days. The fastest record has an unusually short interval; please check the original source.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
